Mendus says updated five-year ADVANCE II vididencel follow-up data are presented at AML immunotherapy workshop

• Mendus flagged updated long-term ADVANCE II trial results in AML, already presented at a Bologna immunotherapy workshop.
• The update supported durable disease control in many patients, with a favorable safety profile driven mainly by manageable injection-site reactions.
• Progress on the Phase 1b VITAL-CML study was also presented, with enrollment ongoing following completion of the initial safety stage.
• Early molecular response data are expected in Q4 2026; topline results are targeted for mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mendus AB (publ) published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.